Repligen (RGEN) Tops Q3 EPS by 7c, Offers Guidance
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $167.60 -1.19%
EPS Growth %: 0.0%
Financial Fact:
Cost of product revenue: 11.24M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: 0.0%
Financial Fact:
Cost of product revenue: 11.24M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.23, $0.07 better than the analyst estimate of $0.16. Revenue for the quarter came in at $141.2 million versus the consensus estimate of $140.67 million.
GUIDANCE:
Repligen sees FY2023 EPS of $1.70-$1.76, versus the consensus of $1.74. Repligen sees FY2023 revenue of $635-645 million, versus the consensus of $646 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Computacenter Plc. (CCC:LN) PT Raised to GBP60 at JPMorgan
- Guidewire Software (GWRE) Tops Q4 EPS by 6c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
